HOME > ¥ä¥Þ¥Î¡¼¥È > ¡ÚÆý¤¬¤ó½Ñ¸å¤ÈÅл³¡ÛÈÖ³°ÊÔ
ÏÀʸ¾Ò²ð¡¡Æý¤¬¤óÀ¸Â¸¼Ô¤Ë¤ª¤±¤ë¡¢¸Ä¡¹¤Î´µ¼Ô¤Ë¹ç¤ï¤»¤¿±¿Æ°Àïά¤È»à˴Ψ¡£
Ä«¤ÎÆü²Ý¤Ç¤Î¿·ÃåÏÀʸ¥Á¥§¥Ã¥¯¤ÇɽÂê¤ÎÏÀʸ¤¬¤¢¤ê¤Þ¤·¤¿¤Î¤ÇÆâÍÆ¤ò¥·¥§¥¢¤·¤Þ¤¹¡£
¢£ ÏÀʸÍ×Ìó
JAMA Network Open. 2026;
Brown JC, et al.
Tailored Exercise Strategies and Mortality Among Breast Cancer Survivors.
PMID: 41973424
¸¶Ê¸ÏÀʸ¤Ø¤Î¥ê¥ó¥¯¤Ï¤³¤Á¤é¡§https://pmc.ncbi.nlm.nih.gov/articles/PMC13077521/
1. ÇØ·Ê
Æý¤¬¤ó¥µ¥Ð¥¤¥Ð¡¼¤Ë¤ª¤¤¤Æ±¿Æ°¤Ïͽ¸å²þÁ±¤È´ØÏ¢¤¹¤ë²ÄǽÀ¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤ë¤¬¡¢¡Ö¤É¤Î¤è¤¦¤Ê±¿Æ°Àïά¤¬Í¸ú¤«¡×¤ÏÌÀ³Î¤Ç¤Ï¤Ê¤¤¡£ÆÃ¤Ë¼ÂÎ×¾²¤Ç¤Ï´µ¼Ô¤´¤È¤Î¾õÂÖº¹¤¬Â礤¯¡¢°ìΧ¤Î±¿Æ°½èÊý¤Ï¸½¼ÂŪ¤Ç¤Ê¤¤¡£
2. ÌÜŪ
¸ÄÊ̲½¤µ¤ì¤¿±¿Æ°Àïά¡Êtailored exercise strategies¡Ë¤¬¡¢Ä¹´ü»à˴Ψ¡ÊÁ´»àË´¡¦Æý¤¬¤óÆÃ°ÛŪ»àË´¡Ë¤È¤É¤Î¤è¤¦¤Ë´ØÏ¢¤¹¤ë¤«¤ò¸¡¾Ú¤¹¤ë¡£
3. ÊýË¡
´Ñ»¡¥Ç¡¼¥¿¤òÍѤ¤¤¿ target trial emulation¡Ê²¾ÁÛ¥é¥ó¥À¥à²½»î¸³¡Ë ¥Ç¥¶¥¤¥ó¡£
Æý¤¬¤ó¥µ¥Ð¥¤¥Ð¡¼Ìó2000Îã¤òÂоݤˡ¢»þ´Ö·Ð²á¤Ë±þ¤¸¤Æ±¿Æ°Î̤òÄ´À°¡¦Áý²Ã¤µ¤»¤ëÀïά¤òɾ²Á¡£¸òÍí°ø»Ò¤òÅý·×Ū¤ËÊäÀµ¤·¡¢10ǯ¥¢¥¦¥È¥«¥à¤ò¿äÄê¡£
4. ·ë²Ì
¸ÄÊ̲½¤µ¤ì¤¿±¿Æ°Àïά¤Ï¡¢10ǯÁ´»à˴Ψ¤ÎÄã²¼¤È´ØÏ¢¤·¡¢Æý¤¬¤óÆÃ°ÛŪ»à˴Ψ¤ÎÄã²¼¤È´ØÏ¢¤ò¼¨¤·¤¿¡£
±¿Æ°Î̤Ȥ·¤Æ¤Ï¡¢½µ75ʬ¤Î¹â¶¯ÅÙ±¿Æ°¡¢¤Þ¤¿¤Ï¡¢½µ120ʬ¤ÎÃæÅùÅÙ±¿Æ°ÄøÅÙ¤ËÁêÅö¤¹¤ë¥ì¥Ù¥ë¤Þ¤Ç¤ÎÅþ㤬°ì¤Ä¤Î´ð½à¤È¤·¤ÆÀßÄꤵ¤ì¤Æ¤¤¤ë¡£
5. ²ò¼á
½ÅÍפʤΤϱ¿Æ°Î̤½¤Î¤â¤Î¤è¤ê¤â¡¢
¸ÄÊ̤ξõÂ֤˱þ¤¸¤ÆÃʳ¬Åª¤Ë±¿Æ°¤òÁý¤ä¤¹¤È¤¤¤¦¡Ö¸ÄÊ̲½Àïά¡×¤Ë¤¢¤ë¡£
6. ¸Â³¦
Ëܸ¦µæ¤Ï´Ñ»¡¸¦µæ¤Ç¤¢¤ê¡¢»Ä;¸òÍí¤Î²ÄǽÀ·ò¹¯¤Ê¿Í¤Û¤É±¿Æ°¤·¤Æ¤¤¤ë¥Ð¥¤¥¢¥¹¤ò´°Á´¤Ë¤ÏÇÓ½ü¤Ç¤¤Ê¤¤¡£
Ãø¼Ô¤Ï¡¢ºÇ½ªÅª¸¡¾Ú¤Ë¤Ï¥é¥ó¥À¥à²½»î¸³¤¬É¬ÍפȷëÏÀ¤·¤Æ¤¤¤ë¡£
¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö
keennjii¤Î¹Í»¡¡§
¤³¤Î·ë²Ì¤Ï¡¢¤³¤ì¤Þ¤Ç¤Î¥³¥é¥à¤Ç½ñ¤¤¤Æ¤¤¿ÆâÍÆ¤È¤Û¤ÜƱ¤¸¤Ç¤¹¡£
¤Ä¤Þ¤ê¡¢±¿Æ°¤Ï¡Ö¤ä¤Ã¤Æ¤¤¤¤¡×¤Ç¤Ï¤Ê¤¯¡¢Í½¸å¤Ë±Æ¶Á¤·¤¦¤ë²ðÆþ¤Ç¤¹¡£
ÆÃ¤ËÃíÌܤ¹¤Ù¤¤ÏÁ´À¸Â¸Î¨¡ÊOS)¤Î²þÁ±¤Ç¤¹¡£
½Ñ¸å¤ÎºÆÈ¯Í½ËɤÇÅêÍ¿¤·¤Þ¤¹¹³¤¬¤óºÞ¤ÇOS¤òͰդ˲þÁ±¤µ¤»¤ë¤Î¤Ï´Êñ¤Ç¤Ï¤Ê¤¯¡¢»î¸³¤Ë¤è¤Ã¤Æ¤Ï¼¨¤»¤Ê¤¤¤³¤È¤â¿¤¤Ãæ¤Ç¡¢±¿Æ°¤Ç¤½¤³¤Ëº¹¤¬½Ð¤Æ¤¤¤ëÅÀ¤Ï½Å¤¤°ÕÌ£¤¬¤¢¤ê¤Þ¤¹¡£
¤Á¤Ê¤ß¤Ë¡¢Æý¤¬¤ó¼ê½Ñ¸å¤Î¼£ÎŤÇOS¤Î²þÁ±¤¬³Îǧ¤µ¤ì¤Æ¤¤¤ë¼ç¤Ê¼£ÎŤϡ¦¡¦¡¦
¢£ HER2ÍÛÀÆý¤¬¤ó
¡¦¹³¤¬¤óºÞ¡Ê¥¢¥ó¥¹¥é¥µ¥¤¥¯¥ê¥ó·Ï¡Ü¥¿¥¥µ¥ó·Ï¡Ë¡Ü¥È¥é¥¹¥Ä¥º¥Þ¥Ö¡Ê¹³HER2Ìô¡Ë
¢£ ¥È¥ê¥×¥ë¥Í¥¬¥Æ¥£¥ÖÆý¤¬¤ó
¡¦¹³¤¬¤óºÞ¡Ê¥¢¥ó¥¹¥é¥µ¥¤¥¯¥ê¥ó·Ï¡Ü¥¿¥¥µ¥ó·Ï¡Ë
¡¦¹³¤¬¤óºÞ¡Ü¥Ú¥à¥Ö¥í¥ê¥º¥Þ¥Ö¡ÊÌȱÖÎÅË¡¡Ë
¢£ ¥Û¥ë¥â¥ó¼õÍÆÂÎÍÛÀ¡¦HER2±¢ÀÆý¤¬¤ó
¡¦¹³¤¬¤óºÞñÆÈ¤ÇÀ¸Â¸Î¨¤òÌÀ³Î¤Ë²þÁ±¤·¤¿¼£ÎŤϤϤä¤ê¤·¤Ê¤¤
¡ÊÀ¸Â¸Î¨²þÁ±¤ÎÃæ¿´¤Ï¥Û¥ë¥â¥óÎÅË¡¡Ë
¤Ç¤¹¤¬¡¢OS¤Î²þÁ±¤·¤¦¤ëÌôºÞ¤Ã¤Æ¤½¤¦´Êñ¤Ë¤Ï¤Ç¤Ê¤¤¤ó¤Ç¤¹¤è¤Í¡£Íýͳ¤Ï¤Þ¤¿¤Îµ¡²ñ¤Ë¤Ç¤â½Ò¤Ù¤Þ¤¹¡£
¤½¤ó¤Ê´Êñ¤ËOS²þÁ±¤¬¾ÚÌÀ¤µ¤ì¤Ê¤¤ÌôºÞ¤¬Â¿¤¤¤Î¤Ë¡¢±¿Æ°¤¹¤ë¤³¤È¤¬OS²þÁ±´óÍ¿¤Î²ÄǽÀ¤¬¤¢¤ë¤È¤Ï¤¹¤´¤¤¤³¤È¤Ê¤ó¤Ç¤¹¡£
¤â¤Á¤í¤ó´Ñ»¡¸¦µæ¤Ê¤Î¤Çñ½ãÈæ³Ó¤Ï¤Ç¤¤Þ¤»¤ó¤¬¡¢
¾¯¤Ê¤¯¤È¤â¡Ö°ÂÀŤ¬°ÂÁ´¡×¤È¤¤¤¦È¯ÁۤǤϤʤ¤¡¢¤È¤¤¤¦Êý¸þÀ¤ÏÌÀ³Î¤Ç¤¹¡£
¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö
¡ùÊäÂÀâÌÀ¡Ê¤Ä¤¤¤Ç¤ËÃÎ¤ÃÆÀ¡Ë¡ù
¾åµ¤Î¡Ö6¸Â³¦¡×¤Ë½ñ¤¤Þ¤·¤¿¡¢´Ñ»¡¸¦µæ¤È¥é¥ó¥À¥à²½»î¸³¤Ã¤Æ¤Ê¤Ë¡ª¡ª¡©¡©
2¤Ä¤Î°ã¤¤¤Ï¡ÖÈæ¤ÙÊý¤Î¸·Ì©¤µ¡×¤Ç¤¹¡£
´Ñ»¡¸¦µæ¤Ï¡¢
¡Ö¼ÂºÝ¤ÎÀ¸³è¤ÎÃæ¤Ç¤É¤¦¤Ê¤Ã¤Æ¤¤¤ë¤«¡×¤ò¤½¤Î¤Þ¤Þ¸«¤ë¸¦µæ¤Ç¤¹¡£
¤¿¤È¤¨¤Ð¡¢¤è¤¯±¿Æ°¤·¤Æ¤¤¤ë¿Í¤È¡¢¤¢¤Þ¤ê¤·¤Ê¤¤¿Í¤òÈæ¤Ù¤Æ¡Ö±¿Æ°¤·¤Æ¤¤¤ë¿Í¤ÎÊý¤¬Ä¹À¸¤¤À¤Ã¤¿¡×¤È¤¤¤¦·ë²Ì¤¬½Ð¤Þ¤¹¡£
¤¿¤À¤·¤³¤³¤Ë¤ÏÌäÂ꤬¤¢¤Ã¤Æ¡¢
±¿Æ°¤·¤Æ¤¤¤ë¿Í¤Ï¤â¤È¤â¤È·ò¹¯°Õ¼±¤¬¹â¤¤¡¢À¸³è½¬´·¤¬Îɤ¤¡¢¤Ê¤É¤Î°ã¤¤¤¬º®¤¶¤Ã¤Æ¤¤¤Þ¤¹¡£¤Ä¤Þ¤ê¡¢¡Ö±¿Æ°¤Î¤»¤¤¤ÇÎɤ¯¤Ê¤Ã¤¿¤Î¤«¡×¤Ï´°Á´¤Ë¤Ïʬ¤«¤ê¤Þ¤»¤ó¡£
¡Ê¤³¤ì¤ò¥»¥ì¥¯¥·¥ç¥ó¥Ð¥¤¥¢¥¹¤È¤¤¤¤¤Þ¤¹¡£¡Ë
°ìÊý¡¢RCT¡Ê¥é¥ó¥À¥à²½»î¸³¡Ë¤Ï¡¢¿Í¤ò¥é¥ó¥À¥à¤Ëʬ¤±¤ÆÈæ¤Ù¤Þ¤¹¡£
¤¿¤È¤¨¤Ð¡¢
A¥°¥ë¡¼¥×¡§±¿Æ°¤·¤Æ¤â¤é¤¦
B¥°¥ë¡¼¥×¡§±¿Æ°¤·¤Ê¤¤
¤È̵ºî°Ù¤Ë³ä¤ê¿¶¤ë¡Ê¤¯¤¸°ú¤¡Ë¤³¤È¤Ç¡¢¤â¤È¤â¤È¤ÎÂμÁ¤äÀ¸³è¤Îº¹¤òÊ¿¶Ñ²½¤·¤Þ¤¹¡£¤½¤Î¾å¤Çº¹¤¬½Ð¤ì¤Ð¡¢¡Ö±¿Æ°¤Î¸ú²Ì¡×¤È¤«¤Ê¤ê¸À¤¤¤ä¤¹¤¯¤Ê¤ê¤Þ¤¹¡£
¤Ä¤Þ¤ê¡¢
´Ñ»¡¸¦µæ¡§¸½¼Â¤Ë¶á¤¤¤¬¡¢¸¶°ø¤Ï¤Ï¤Ã¤¤ê¤·¤Ê¤¤
RCT¡§¸¶°ø¤Ï¤Ï¤Ã¤¤ê¤·¤ä¤¹¤¤¤¬¡¢¾ò·ï¤Ï¿Í¹©Åª
¤È¤Ê¤ê¤Þ¤¹¡£
°ì¸À¤Ç¤¤¤¦¤È¡¢
´Ñ»¡¸¦µæ¤Ï¡Ö´Ø·¸¤¬¤¢¤ë¤«¤ò¸«¤ë¡×
RCT¤Ï¡ÖËÜÅö¤Ë¤½¤ì¤¬¸¶°ø¤«¤ò³Î¤«¤á¤ë¡×¸¦µæ¤Ç¤¹¡£
¢£ ÏÀʸÍ×Ìó
JAMA Network Open. 2026;
Brown JC, et al.
Tailored Exercise Strategies and Mortality Among Breast Cancer Survivors.
PMID: 41973424
¸¶Ê¸ÏÀʸ¤Ø¤Î¥ê¥ó¥¯¤Ï¤³¤Á¤é¡§https://pmc.ncbi.nlm.nih.gov/articles/PMC13077521/
1. ÇØ·Ê
Æý¤¬¤ó¥µ¥Ð¥¤¥Ð¡¼¤Ë¤ª¤¤¤Æ±¿Æ°¤Ïͽ¸å²þÁ±¤È´ØÏ¢¤¹¤ë²ÄǽÀ¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤ë¤¬¡¢¡Ö¤É¤Î¤è¤¦¤Ê±¿Æ°Àïά¤¬Í¸ú¤«¡×¤ÏÌÀ³Î¤Ç¤Ï¤Ê¤¤¡£ÆÃ¤Ë¼ÂÎ×¾²¤Ç¤Ï´µ¼Ô¤´¤È¤Î¾õÂÖº¹¤¬Â礤¯¡¢°ìΧ¤Î±¿Æ°½èÊý¤Ï¸½¼ÂŪ¤Ç¤Ê¤¤¡£
2. ÌÜŪ
¸ÄÊ̲½¤µ¤ì¤¿±¿Æ°Àïά¡Êtailored exercise strategies¡Ë¤¬¡¢Ä¹´ü»à˴Ψ¡ÊÁ´»àË´¡¦Æý¤¬¤óÆÃ°ÛŪ»àË´¡Ë¤È¤É¤Î¤è¤¦¤Ë´ØÏ¢¤¹¤ë¤«¤ò¸¡¾Ú¤¹¤ë¡£
3. ÊýË¡
´Ñ»¡¥Ç¡¼¥¿¤òÍѤ¤¤¿ target trial emulation¡Ê²¾ÁÛ¥é¥ó¥À¥à²½»î¸³¡Ë ¥Ç¥¶¥¤¥ó¡£
Æý¤¬¤ó¥µ¥Ð¥¤¥Ð¡¼Ìó2000Îã¤òÂоݤˡ¢»þ´Ö·Ð²á¤Ë±þ¤¸¤Æ±¿Æ°Î̤òÄ´À°¡¦Áý²Ã¤µ¤»¤ëÀïά¤òɾ²Á¡£¸òÍí°ø»Ò¤òÅý·×Ū¤ËÊäÀµ¤·¡¢10ǯ¥¢¥¦¥È¥«¥à¤ò¿äÄê¡£
4. ·ë²Ì
¸ÄÊ̲½¤µ¤ì¤¿±¿Æ°Àïά¤Ï¡¢10ǯÁ´»à˴Ψ¤ÎÄã²¼¤È´ØÏ¢¤·¡¢Æý¤¬¤óÆÃ°ÛŪ»à˴Ψ¤ÎÄã²¼¤È´ØÏ¢¤ò¼¨¤·¤¿¡£
±¿Æ°Î̤Ȥ·¤Æ¤Ï¡¢½µ75ʬ¤Î¹â¶¯ÅÙ±¿Æ°¡¢¤Þ¤¿¤Ï¡¢½µ120ʬ¤ÎÃæÅùÅÙ±¿Æ°ÄøÅÙ¤ËÁêÅö¤¹¤ë¥ì¥Ù¥ë¤Þ¤Ç¤ÎÅþ㤬°ì¤Ä¤Î´ð½à¤È¤·¤ÆÀßÄꤵ¤ì¤Æ¤¤¤ë¡£
5. ²ò¼á
½ÅÍפʤΤϱ¿Æ°Î̤½¤Î¤â¤Î¤è¤ê¤â¡¢
¸ÄÊ̤ξõÂ֤˱þ¤¸¤ÆÃʳ¬Åª¤Ë±¿Æ°¤òÁý¤ä¤¹¤È¤¤¤¦¡Ö¸ÄÊ̲½Àïά¡×¤Ë¤¢¤ë¡£
6. ¸Â³¦
Ëܸ¦µæ¤Ï´Ñ»¡¸¦µæ¤Ç¤¢¤ê¡¢»Ä;¸òÍí¤Î²ÄǽÀ·ò¹¯¤Ê¿Í¤Û¤É±¿Æ°¤·¤Æ¤¤¤ë¥Ð¥¤¥¢¥¹¤ò´°Á´¤Ë¤ÏÇÓ½ü¤Ç¤¤Ê¤¤¡£
Ãø¼Ô¤Ï¡¢ºÇ½ªÅª¸¡¾Ú¤Ë¤Ï¥é¥ó¥À¥à²½»î¸³¤¬É¬ÍפȷëÏÀ¤·¤Æ¤¤¤ë¡£
¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö
keennjii¤Î¹Í»¡¡§
¤³¤Î·ë²Ì¤Ï¡¢¤³¤ì¤Þ¤Ç¤Î¥³¥é¥à¤Ç½ñ¤¤¤Æ¤¤¿ÆâÍÆ¤È¤Û¤ÜƱ¤¸¤Ç¤¹¡£
¤Ä¤Þ¤ê¡¢±¿Æ°¤Ï¡Ö¤ä¤Ã¤Æ¤¤¤¤¡×¤Ç¤Ï¤Ê¤¯¡¢Í½¸å¤Ë±Æ¶Á¤·¤¦¤ë²ðÆþ¤Ç¤¹¡£
ÆÃ¤ËÃíÌܤ¹¤Ù¤¤ÏÁ´À¸Â¸Î¨¡ÊOS)¤Î²þÁ±¤Ç¤¹¡£
½Ñ¸å¤ÎºÆÈ¯Í½ËɤÇÅêÍ¿¤·¤Þ¤¹¹³¤¬¤óºÞ¤ÇOS¤òͰդ˲þÁ±¤µ¤»¤ë¤Î¤Ï´Êñ¤Ç¤Ï¤Ê¤¯¡¢»î¸³¤Ë¤è¤Ã¤Æ¤Ï¼¨¤»¤Ê¤¤¤³¤È¤â¿¤¤Ãæ¤Ç¡¢±¿Æ°¤Ç¤½¤³¤Ëº¹¤¬½Ð¤Æ¤¤¤ëÅÀ¤Ï½Å¤¤°ÕÌ£¤¬¤¢¤ê¤Þ¤¹¡£
¤Á¤Ê¤ß¤Ë¡¢Æý¤¬¤ó¼ê½Ñ¸å¤Î¼£ÎŤÇOS¤Î²þÁ±¤¬³Îǧ¤µ¤ì¤Æ¤¤¤ë¼ç¤Ê¼£ÎŤϡ¦¡¦¡¦
¢£ HER2ÍÛÀÆý¤¬¤ó
¡¦¹³¤¬¤óºÞ¡Ê¥¢¥ó¥¹¥é¥µ¥¤¥¯¥ê¥ó·Ï¡Ü¥¿¥¥µ¥ó·Ï¡Ë¡Ü¥È¥é¥¹¥Ä¥º¥Þ¥Ö¡Ê¹³HER2Ìô¡Ë
¢£ ¥È¥ê¥×¥ë¥Í¥¬¥Æ¥£¥ÖÆý¤¬¤ó
¡¦¹³¤¬¤óºÞ¡Ê¥¢¥ó¥¹¥é¥µ¥¤¥¯¥ê¥ó·Ï¡Ü¥¿¥¥µ¥ó·Ï¡Ë
¡¦¹³¤¬¤óºÞ¡Ü¥Ú¥à¥Ö¥í¥ê¥º¥Þ¥Ö¡ÊÌȱÖÎÅË¡¡Ë
¢£ ¥Û¥ë¥â¥ó¼õÍÆÂÎÍÛÀ¡¦HER2±¢ÀÆý¤¬¤ó
¡¦¹³¤¬¤óºÞñÆÈ¤ÇÀ¸Â¸Î¨¤òÌÀ³Î¤Ë²þÁ±¤·¤¿¼£ÎŤϤϤä¤ê¤·¤Ê¤¤
¡ÊÀ¸Â¸Î¨²þÁ±¤ÎÃæ¿´¤Ï¥Û¥ë¥â¥óÎÅË¡¡Ë
¤Ç¤¹¤¬¡¢OS¤Î²þÁ±¤·¤¦¤ëÌôºÞ¤Ã¤Æ¤½¤¦´Êñ¤Ë¤Ï¤Ç¤Ê¤¤¤ó¤Ç¤¹¤è¤Í¡£Íýͳ¤Ï¤Þ¤¿¤Îµ¡²ñ¤Ë¤Ç¤â½Ò¤Ù¤Þ¤¹¡£
¤½¤ó¤Ê´Êñ¤ËOS²þÁ±¤¬¾ÚÌÀ¤µ¤ì¤Ê¤¤ÌôºÞ¤¬Â¿¤¤¤Î¤Ë¡¢±¿Æ°¤¹¤ë¤³¤È¤¬OS²þÁ±´óÍ¿¤Î²ÄǽÀ¤¬¤¢¤ë¤È¤Ï¤¹¤´¤¤¤³¤È¤Ê¤ó¤Ç¤¹¡£
¤â¤Á¤í¤ó´Ñ»¡¸¦µæ¤Ê¤Î¤Çñ½ãÈæ³Ó¤Ï¤Ç¤¤Þ¤»¤ó¤¬¡¢
¾¯¤Ê¤¯¤È¤â¡Ö°ÂÀŤ¬°ÂÁ´¡×¤È¤¤¤¦È¯ÁۤǤϤʤ¤¡¢¤È¤¤¤¦Êý¸þÀ¤ÏÌÀ³Î¤Ç¤¹¡£
¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö¡ö
¡ùÊäÂÀâÌÀ¡Ê¤Ä¤¤¤Ç¤ËÃÎ¤ÃÆÀ¡Ë¡ù
¾åµ¤Î¡Ö6¸Â³¦¡×¤Ë½ñ¤¤Þ¤·¤¿¡¢´Ñ»¡¸¦µæ¤È¥é¥ó¥À¥à²½»î¸³¤Ã¤Æ¤Ê¤Ë¡ª¡ª¡©¡©
2¤Ä¤Î°ã¤¤¤Ï¡ÖÈæ¤ÙÊý¤Î¸·Ì©¤µ¡×¤Ç¤¹¡£
´Ñ»¡¸¦µæ¤Ï¡¢
¡Ö¼ÂºÝ¤ÎÀ¸³è¤ÎÃæ¤Ç¤É¤¦¤Ê¤Ã¤Æ¤¤¤ë¤«¡×¤ò¤½¤Î¤Þ¤Þ¸«¤ë¸¦µæ¤Ç¤¹¡£
¤¿¤È¤¨¤Ð¡¢¤è¤¯±¿Æ°¤·¤Æ¤¤¤ë¿Í¤È¡¢¤¢¤Þ¤ê¤·¤Ê¤¤¿Í¤òÈæ¤Ù¤Æ¡Ö±¿Æ°¤·¤Æ¤¤¤ë¿Í¤ÎÊý¤¬Ä¹À¸¤¤À¤Ã¤¿¡×¤È¤¤¤¦·ë²Ì¤¬½Ð¤Þ¤¹¡£
¤¿¤À¤·¤³¤³¤Ë¤ÏÌäÂ꤬¤¢¤Ã¤Æ¡¢
±¿Æ°¤·¤Æ¤¤¤ë¿Í¤Ï¤â¤È¤â¤È·ò¹¯°Õ¼±¤¬¹â¤¤¡¢À¸³è½¬´·¤¬Îɤ¤¡¢¤Ê¤É¤Î°ã¤¤¤¬º®¤¶¤Ã¤Æ¤¤¤Þ¤¹¡£¤Ä¤Þ¤ê¡¢¡Ö±¿Æ°¤Î¤»¤¤¤ÇÎɤ¯¤Ê¤Ã¤¿¤Î¤«¡×¤Ï´°Á´¤Ë¤Ïʬ¤«¤ê¤Þ¤»¤ó¡£
¡Ê¤³¤ì¤ò¥»¥ì¥¯¥·¥ç¥ó¥Ð¥¤¥¢¥¹¤È¤¤¤¤¤Þ¤¹¡£¡Ë
°ìÊý¡¢RCT¡Ê¥é¥ó¥À¥à²½»î¸³¡Ë¤Ï¡¢¿Í¤ò¥é¥ó¥À¥à¤Ëʬ¤±¤ÆÈæ¤Ù¤Þ¤¹¡£
¤¿¤È¤¨¤Ð¡¢
A¥°¥ë¡¼¥×¡§±¿Æ°¤·¤Æ¤â¤é¤¦
B¥°¥ë¡¼¥×¡§±¿Æ°¤·¤Ê¤¤
¤È̵ºî°Ù¤Ë³ä¤ê¿¶¤ë¡Ê¤¯¤¸°ú¤¡Ë¤³¤È¤Ç¡¢¤â¤È¤â¤È¤ÎÂμÁ¤äÀ¸³è¤Îº¹¤òÊ¿¶Ñ²½¤·¤Þ¤¹¡£¤½¤Î¾å¤Çº¹¤¬½Ð¤ì¤Ð¡¢¡Ö±¿Æ°¤Î¸ú²Ì¡×¤È¤«¤Ê¤ê¸À¤¤¤ä¤¹¤¯¤Ê¤ê¤Þ¤¹¡£
¤Ä¤Þ¤ê¡¢
´Ñ»¡¸¦µæ¡§¸½¼Â¤Ë¶á¤¤¤¬¡¢¸¶°ø¤Ï¤Ï¤Ã¤¤ê¤·¤Ê¤¤
RCT¡§¸¶°ø¤Ï¤Ï¤Ã¤¤ê¤·¤ä¤¹¤¤¤¬¡¢¾ò·ï¤Ï¿Í¹©Åª
¤È¤Ê¤ê¤Þ¤¹¡£
°ì¸À¤Ç¤¤¤¦¤È¡¢
´Ñ»¡¸¦µæ¤Ï¡Ö´Ø·¸¤¬¤¢¤ë¤«¤ò¸«¤ë¡×
RCT¤Ï¡ÖËÜÅö¤Ë¤½¤ì¤¬¸¶°ø¤«¤ò³Î¤«¤á¤ë¡×¸¦µæ¤Ç¤¹¡£
¤½¤Î7¡¡²¹Àô¤ËÆþ¤ë¤«±£¤¹¤« ¡½ Åл³¸å¤Î¡È¸«¤¨¤Ê¤¤°Õ»×·èÄê¡É¡¡¤Ï¤³¤Á¤é
Ãø¼Ô¤Î¥ä¥Þ¥ì¥³¥Ú¡¼¥¸¤Ç¤Î¤³¤ÎÆüµ¤Ë¡¢¤â¤È¤â¤ÈµºÜ¤·¤Æ¤¤¤¿ÆâÍÆ¤ò¥ä¥Þ¥Î¡¼¥È¤Ëžµ¤·¤Æ¤ª¤ê¤Þ¤¹¡£
¤³¤Îµ»ö¤ËÂФ¹¤ë¤´°Õ¸«¡¢¥³¥á¥ó¥È¤Ï¾®À¸¤Î¥ä¥Þ¥ì¥³¥Ú¡¼¥¸¤Ç¤ÎÆüµ¤Ë¤Æ¤ª´ê¤¤¤¤¤¿¤·¤Þ¤¹¡£
¤³¤Îµ»ö¤ËÂФ¹¤ë¤´°Õ¸«¡¢¥³¥á¥ó¥È¤Ï¾®À¸¤Î¥ä¥Þ¥ì¥³¥Ú¡¼¥¸¤Ç¤ÎÆüµ¤Ë¤Æ¤ª´ê¤¤¤¤¤¿¤·¤Þ¤¹¡£
¤ªµ¤¤ËÆþ¤ê¤·¤¿¿Í
¿Í
Çï¼ê¤Ç±þ±ç
Çï¼ê¤·¤¿¿Í
Çï¼ê
keenjii¤µ¤ó¤Îµ»ö°ìÍ÷
-
¥³¥é¥à¡Ö°å³ØÅª¤Ë¡£¡×¤½¤Î¢
4
¹¹¿·Æü¡§2026ǯ05·î09Æü
-
¥³¥é¥à¡Ö°å³ØÅª¤Ë¡£¡×¤½¤Î¡
4
¹¹¿·Æü¡§2026ǯ05·î09Æü
-
¡ÚÆý¤¬¤ó½Ñ¸å¤ÈÅл³¡ÛÈÖ³°ÊÔ
1
¹¹¿·Æü¡§2026ǯ05·î09Æü
¢¨¤³¤Îµ»ö¤Ï¥ä¥Þ¥ì¥³¤Î¡Ö¥ä¥Þ¥Î¡¼¥È¡×µ¡Ç½¤òÍøÍѤ·¤Æºî¤é¤ì¤Æ¤¤¤Þ¤¹¡£
¤É¤Ê¤¿¤Ç¤â¡¢»³¤Ë´Ø¤¹¤ëÃμ±¤äµ»½Ñ¤Ê¤É¤Î¥Î¥¦¥Ï¥¦¤ò´Êñ¤Ë»Ä¤·¤Æ¶¦Í¤Ç¤¤Þ¤¹¡£
¤¼¤Ò¤´¶¨ÎϤ¯¤À¤µ¤¤¡ª



¥³¥á¥ó¥È¤òÊÔ½¸
¤¤¤¤¤Í¤·¤¿¿Í
¥³¥á¥ó¥È¤ò½ñ¤¯
¥ä¥Þ¥ì¥³¤Ë¥æ¡¼¥¶¡¼ÅÐÏ¿¤¤¤¿¤À¤¡¢¥í¥°¥¤¥ó¤·¤Æ¤¤¤¿¤À¤¯¤³¤È¤Ë¤è¤Ã¤Æ¡¢¥³¥á¥ó¥È¤¬½ñ¤±¤ë¤è¤¦¤Ë¤Ê¤ê¤Þ¤¹¡£¥ä¥Þ¥ì¥³¤Ë¥æ¡¼¥¶ÅÐÏ¿¤¹¤ë